Vioxx Fallout Still Hangs Heavy Over FDA Advisory Committees
Executive Summary
Four years after Merck removed Vioxx from the market, FDA's advisory committee members are still wary of making a similar mistake. At a July 29 Arthritis Advisory Committee meeting for Roche's Actemra (tocilizumab), panel members expressed concern that elevated LDL levels could portend increased risk of CV events
You may also be interested in...
Roche’s Actemra Postmarket Safety Plan May Obviate Need For REMS
Roche may have staved off the imposition of a REMS for its rheumatoid arthritis candidate Actemra by proposing a robust pharmacovigilance of its own
Roche’s Actemra Postmarket Safety Plan May Obviate Need For REMS
Roche may have staved off the imposition of a REMS for its rheumatoid arthritis candidate Actemra by proposing a robust pharmacovigilance of its own
COX-2 Market Growth Could Be Stalled Until Release Of Long-Term Safety Data
The effect of the Vioxx withdrawal on the non-steroidal anti-inflammatory drug market will likely be determined by long-term studies of marketed products